4.6 Review

Unraveling the Role of Innate Lymphoid Cells in Acute Myeloid Leukemia

Journal

CANCERS
Volume 13, Issue 2, Pages -

Publisher

MDPI
DOI: 10.3390/cancers13020320

Keywords

AML; ILC; immunotherapy; AHR; NK

Categories

Funding

  1. National Institutes of Health/National Cancer Institute [5K22CA218466-02, CA199447, CA208353, CA068458, CA210087]
  2. American Association for Cancer Research award [17-20-46-MUND]
  3. American Cancer Society [RSG-20-051-01-LIB]
  4. Pelotonia Organization (OSU-CCC)

Ask authors/readers for more resources

AML is an aggressive form of blood cancer with poor survival rates. Patients with AML often have defects in their immune system, particularly in NK cells. Recent studies are shedding light on the role of other ILC family members in AML, enhancing our understanding of AML treatment.
Simple Summary Acute myeloid leukemia (AML) is an aggressive form of cancer found in the blood and bone marrow with poor survival rates. Patients with AML are known to have many defects in their immune system which render immune cells unable to detect and/or kill cancer cells. Natural Killer (NK) cells are innate immune effector cells responsible for surveying the body to eliminate cancer cells as well as alert other immune cells to help clear the cancer cells. NK cells have developmental and functional defects in AML patients. While advances have been made to understand these NK cell defects in the setting of AML, the role of other closely related and recently discovered members of the innate lymphoid cell (ILC) family is much less clear. The ILC family is comprised of NK cells, ILC1s, ILC2s, and ILC3s, and due in part to their recent discovery, non-NK ILCs are just now beginning to be investigated in the setting of AML. By better understanding how AML alters the normal function of these cell types, and how the alteration regulates AML growth, we may be able to target and tailor new forms of therapy for patients. Over the past 50 years, few therapeutic advances have been made in treating acute myeloid leukemia (AML), an aggressive form of blood cancer, despite vast improvements in our ability to classify the disease. Emerging evidence suggests the immune system is important in controlling AML progression and in determining prognosis. Natural killer (NK) cells are important cytotoxic effector cells of the innate lymphoid cell (ILC) family that have been shown to have potent anti-leukemic functions. Recent studies are now revealing impairment or dysregulation of other ILCs in various types of cancers, including AML, which limits the effectiveness of NK cells in controlling cancer progression. NK cell development and function are inhibited in AML patients, which results in worse clinical outcomes; however, the specific roles of other ILC populations in AML are just now beginning to be unraveled. In this review, we summarize what is known about the role of ILC populations in AML.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available